Crewe Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
Other funds holding LGND
VPM
VCM
NAMI
CC
Crewe Advisors's LGND Position: Q1 2026 in Review
Crewe Advisors increased its Ligand Pharmaceuticals (LGND) stake by 27% in Q1 2026, buying an estimated $7.72K and bringing the position to 181 shares worth $36.1K. The position accounts for ﹤0.01% of the portfolio, ranked #408.
Crewe Advisors first reported a position in LGND in Q2 2024 and has held it in 4 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Crewe Advisors held 181 shares of Ligand Pharmaceuticals worth $36.1K as of Q1 2026.
- Crewe Advisors bought 39 Ligand Pharmaceuticals shares in Q1 2026, an estimated $7.72K.
- Ligand Pharmaceuticals made up ﹤0.01% of Crewe Advisors's portfolio in Q1 2026, its #408 holding.
- Crewe Advisors first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 4 quarters since.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Crewe Advisors's 13F filing for Q1 2026, filed 7 May 2026.